Related references
Note: Only part of the references are listed.Synthetic Studies on Selective, Proapoptotic Isomalabaricane Triterpenoids Aided by Computational Techniques
Yaroslav D. Boyko et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2021)
Total Synthesis of Stelletins through an Unconventional Annulation Strategy
Christopher J. Huck et al.
ACCOUNTS OF CHEMICAL RESEARCH (2021)
Natural products in drug discovery: advances and opportunities
Atanas G. Atanasov et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion
Ester Gangoso et al.
CELL (2021)
BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
Shaolu Zhang et al.
CELL DEATH & DISEASE (2021)
Purine metabolism regulates DNA repair and therapy resistance in glioblastoma
Weihua Zhou et al.
NATURE COMMUNICATIONS (2020)
The role of ubiquitination and deubiquitination in cancer metabolism
Tianshui Sun et al.
MOLECULAR CANCER (2020)
Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma
Yufeng Shi et al.
NATURE (2019)
Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment
Anne Dirkse et al.
NATURE COMMUNICATIONS (2019)
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
Yong Fang et al.
CANCER CELL (2019)
Total Synthesis of Isomalabaricane Triterpenoids
Yaroslav D. Boyko et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2019)
A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis
Xiaoyan Xu et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
State-of-the-art strategies for targeting the DNA damage response in cancer
Patrick G. Pilie et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data
Jann N. Sarkaria et al.
NEURO-ONCOLOGY (2018)
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
Chaoyang Sun et al.
CANCER CELL (2018)
A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer
Xinxin Peng et al.
CANCER CELL (2018)
A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples
Han Chen et al.
CELL (2018)
Phosphatidylinositol 3-kinase and isoforms play key roles in metastasis of prostate cancer DU145 cells
Zhe Zhang et al.
FASEB JOURNAL (2018)
Current Challenges and Opportunities in Treating Glioblastoma
Andrea Shergalis et al.
PHARMACOLOGICAL REVIEWS (2018)
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2017)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Overcoming therapeutic resistance in glioblastoma: the way forward
Satoru Osuka et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Transcription elongation factors represent in vivo cancer dependencies in glioblastoma
Tyler E. Miller et al.
NATURE (2017)
Down-Regulation of the Cyclin-Dependent Kinase Inhibitor p57 Is Mediated by Jab1/Csn5 in Hepatocarcinogenesis
Hui Guo et al.
HEPATOLOGY (2016)
NEDD4L Protein Catalyzes Ubiquitination of PIK3CA Protein and Regulates PI3K-AKT Signaling
Zixi Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis
Qian Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma
Carlos Rodrigo Gil del Alcazar et al.
MOLECULAR CANCER RESEARCH (2016)
Stellettin B Induces G1 Arrest, Apoptosis and Autophagy in Human Non-small Cell Lung Cancer A549 Cells via Blocking PI3K/Akt/mTOR Pathway
Ran Wang et al.
SCIENTIFIC REPORTS (2016)
Rad51 Paralogs Remodel Pre-synaptic Rad51 Filaments to Stimulate Homologous Recombination
Martin R. G. Taylor et al.
CELL (2015)
DNA Double-Strand Break Repair Inhibitors as Cancer Therapeutics
Mrinal Srivastava et al.
CHEMISTRY & BIOLOGY (2015)
The structural basis of XRCC1-mediated DNA repair
Robert E. London
DNA REPAIR (2015)
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors
Autumn J. McRee et al.
INVESTIGATIONAL NEW DRUGS (2015)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp et al.
LANCET ONCOLOGY (2014)
In Vitro Antitumor Activity of Stellettin B, a Triterpene from Marine Sponge Jaspis stellifera, on Human Glioblastoma Cancer SF295 Cells
Sheng-An Tang et al.
MARINE DRUGS (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
Robert J. Cardnell et al.
CLINICAL CANCER RESEARCH (2013)
Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide
Ann-Marie Chacko et al.
EXPERT OPINION ON DRUG DELIVERY (2013)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs
Dexin Kong et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP
Nienke A. de Vries et al.
INVESTIGATIONAL NEW DRUGS (2012)
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Yasir H. Ibrahim et al.
CANCER DISCOVERY (2012)
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Ashish Juvekar et al.
CANCER DISCOVERY (2012)
Balancing repair and tolerance of DNA damage caused by alkylating agents
Dragony Fu et al.
NATURE REVIEWS CANCER (2012)
Present and Future of PI3K Pathway Inhibition in Cancer: Perspectives and Limitations
E. Ciraolo et al.
CURRENT MEDICINAL CHEMISTRY (2011)
How were new medicines discovered?
David C. Swinney et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo
J. P. Robinson et al.
ONCOGENE (2011)
Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39
Dexin Kong et al.
EUROPEAN JOURNAL OF CANCER (2010)
γH2AX: a sensitive molecular marker of DNA damage and repair
L-J Mah et al.
LEUKEMIA (2010)
Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair
L. Tian et al.
ONCOGENE (2010)
PTEN and the PI3-Kinase Pathway in Cancer
Nader Chalhoub et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
Gaspar J. Kitange et al.
NEURO-ONCOLOGY (2009)
Homologous recombination in DNA repair and DNA damage tolerance
Xuan Li et al.
CELL RESEARCH (2008)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
DNA-PK-dependent phosphorylation of Ku70/80 is not required for non-homologous end joining
P Douglas et al.
DNA REPAIR (2005)
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
MA Jordan et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions
AE Vidal et al.
EMBO JOURNAL (2001)
Share Paper
